

From: s47F
To: s22 s47F
Subject: RE: Fremanezumab COM [SEC=OFFICIAL]
Date: Tuesday, 17 September 2019 9:14:35 AM
Attachments: [image001.png](#)
[image002.png](#)
[image003.png](#)
[image004.png](#)
[DRAFT 5.06 fremanezumab.COM](#)s47F

Hi s22 ,

Please find attached the fremanezumab commentary with edits.

Please let us know if there's anything further we can do to help finalise the commentary.

Cheers,

s47F

s47F

s47F

s47F

From: s22
Sent: Monday, 16 September 2019 5:14 PM
To: s47F s22 s47F
Subject: RE: Fremanezumab COM [SEC=OFFICIAL]
That is fine, s47F thanks for letting me know.
Cheers,
s22

From: s47F
Sent: Monday, 16 September 2019 5:11 PM
To: s22 s47F
Cc: s22
Subject: RE: Fremanezumab COM [SEC=OFFICIAL]
H s22

We are just finalising the fremanezumab edits and were wondering whether it would be okay to send you the document first thing tomorrow morning?

That would enable us to give it another read through to make sure all the changes flow through

to the main body appropriately.

I'm sorry for the delay – and hope it doesn't put you out too much.

Kind regards,

s47F

s47F



From: s47F

Sent: Thursday, 12 September 2019 4:19 PM

To: s22 s47F

>

Cc: s22

Subject: RE: Fremanezumab COM [SEC=OFFICIAL]

Thanks s22 We'll let you know if we have any issues finalising by Monday.

Cheers,

s47F

s47F

s47F



s47F

From: s22

Sent: Thursday, 12 September 2019 4:09 PM

To: s47F

Cc: s22

Subject: Fremanezumab COM [SEC=OFFICIAL]

Hi s47F

Please find attached our comments on the fremanezumab commentary. Thanks for your work on this. Please flow any changes made to Executive Summary to main body.

The ACM minutes arrived earlier this week – attached.

Happy to discuss anytime if you have questions.

Can we please have a revised version by Monday?

(s47F – s47C – no need to include in Exec Summ for this one s47C. They are in main body of COM is ESC members interested).

Kind regards,

s22

PBAC Secretariat

Office of Health Technology Assessment | Technology Assessment & Access Division

Australian Government Department of Health

s22

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."